RE:RE:RE:RE:Why Ranbaxy?truthseeker2012 wrote: Yes you are right I think in hindsight it was a mistake to market Absorica through Ranbaxy. Lets just hope Sun Pharma can improve things for Absorica in the USA soon.
They said they will make Absorica a priority for their USA market but as you said just the facts and the facts are, things have not gone well for Absorica in the past 2 1/2 quarters with no significant gains in market share.
The marketer of Absorica in the last few quarters for Absorica seems to be snatching defeat from the jaws of certain victory. When one has the superior product by far one is expected and supposed to be the winner.
Does anyone know does Absorica have FDA permission to be marketed without the Ranbaxy technology, or were all of the trials done incorporating Ranbaxy? If Absorica was tested alone, what is the efficacy of Absorica without Ranbaxy versus competitive drugs?
It seems to me that one of the reasons they needed to do the Innocutis deal was to gain a US sales force - directly under their control - that already has dermatologist access.
Has anyone seen figures about how much EBITDA or free cash flow Innocutis currently produces? We are buying two pipeline drugs, but how much are we paying on the cash flows they already produce?